Positive 96-Week Results for Darunavir-Based Single-Tablet Regimen for HIV


A total of 85% of AMBER study participants (308/362) achieved virologic suppression (viral load

New trial results presented at HIV Glasgow in Scotland indicate that the combination of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide (D/C/F/TAF, SYMTUZA, Janssen) is a safe and effective treatment for HIV-1 infection in treatment-naïve and certain virologically suppressed adults.

The combination of darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg was approved in July 2018 as the first and only complete, darunavir-based single-tablet regimen for the treatment of HIV in treatment-naïve and certain virologically-suppressed adults based on the results of the AMBER and EMERALD trials.

A total of 85% of AMBER study participants (308/362) achieved virologic suppression (viral load <50 copies/mL) at week 96 when treated with D/C/F/TAF for HIV infection, according to a statement from Janssen. Six-percent of participants (20/362) had virologic failure (viral load >50 c/mL); however, none of the participants experienced darunavir, primary protease inhibitor, or tenofovir resistance-associated mutations.

For more on this study, visit ContagionLive.com.

Related Videos
Whole psilocybin mushroom in a clear medication capsule | Image credit: Zim - stock.adobe.com
Patient suffering from atopic dermatitis -- Image credit: Nikkikii | stock.adobe.com
Image credit: Fabio Balbi | stock.adobe.com
Image credit: Melita - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
cropped view of man performing chest compression on dummy during cpr training class - Image credit: LIGHTFIELD STUDIOS | stock.adobe.com
Medicine law concept. Judges gavel with pills | Image Credit: Iren Moroz - stock.adobe.com
Image credit: New Africa | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.